Product Information
Phase Detail
Yarra SEC-X300 Phase
Yarra SEC-X300 GFC columns can be used for monoclonal antibodies (mAbs), antibody aggregation, antibody drug conjugates (ADCs), and biosimilars
Yarra SEC-X300 Phase
Yarra SEC-X300 Phase
With a wide molecular weight range (10K – 700KDa) and high efficiency, Yarra SEC-X300 columns are well suited for the ultra-high-resolution separation and characterization of HMW biomolecules and aggregation studies including the following on UHPLC and HPLC systems:
- monoclonal antibodies (mAbs)
- antibody aggregation
- antibody drug conjugates (ADCs)
- biosimilars
Because Yarra SEC-X300 columns typically operate at backpressures below 3,500 psi, they can deliver improved performance (greater resolution, better peak shape and faster analysis time) for existing 3µm and 5µm GFC/SEC column methods on HPLC systems.
Yarra SEC-X300 Documents
Yarra SEC-X300 Documents
Showing 1-3 of 3 results
| Type | Document Title |
|---|---|
| Brochures | United States Pharmacopeia (USP) Allowable Adjustments Guide |
| Brochures | Yarra GFC/SEC Column Product Guide |
| Technical Notes | Mobile Phase Optimization for Aggregate Analysis of Monoclonal Antibodies (TN-1226) |
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.
CONNECT WITH US
